Amgen Builds Up Future Launches As Oncology Biosimilars Slide

Firm Looks To Amjevita, Along With Stelara And Eylea Rivals, For Future Growth

 
• By David Wallace
  
Wooden businessman down up stairs
As Amgen’s oncology biosimilars decline, a lift will come from new products • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products